Literature DB >> 6714269

The metabolic fate of 2H-labelled propafenone in man.

H G Hege, M Hollmann, S Kaumeier, H Lietz.   

Abstract

The metabolism of propafenone was studied in three humans by using 300 mg of the deuterated compound given orally. The excretion of propafenone and its metabolites was assessed by measuring the deuterium content in the excretion products by means of a microwave plasma detector. At selected times the metabolic pattern in plasma, urine, bile and feces was determined. The metabolites were isolated and the structure of the main compounds was characterized. Propafenone is absorbed completely and quantitatively metabolized. Unchanged propafenone is excreted neither in the urine nor in the feces in amounts of more than 1% the dose. The percentage of free unconjugated propafenone of the total deuterium content in the plasma was about 10% 3 and 6 hours after application. Conjugates of hydroxylated derivatives of propafenone are present predominantly in the plasma. The excretion of the metabolites takes place mainly by way of the feces, 53% of the dose is excreted by this route within 48 hours. Urinary elimination accounted for 18.5 and 38% of the dose within 48 hours in two humans. It was possible to elucidate the structure of 11 metabolites, accounting for more than 90% of the dose administered. The major metabolites are conjugates of 5-hydroxypropafenone and hydroxy-methoxy-propafenone with glucuronic and sulphuric acid and propafenone glucuronide. Furthermore, metabolic products of oxydative deamination pathway were identified, i.e. a glycol and a lactic acid derivative. C-C splitting yields a relatively large amount of 3-phenyl-propionic acid, while cleavage of the ether group leads to a phenolic product and is only of minor importance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6714269     DOI: 10.1007/BF03189604

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

1.  O-methylated catechol-like metabolites of propranolol in man.

Authors:  T Walle; E C Conradi; U K Walle; T E Gaffney
Journal:  Drug Metab Dispos       Date:  1978 Jul-Aug       Impact factor: 3.922

2.  Bilary disposition of adriamycin.

Authors:  C E Riggs; R S Benjamin; A A Serpick; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

Review 3.  Analysis of intact glucuronides by mass spectrometry and gas chromatography-mass spectrometry. A review.

Authors:  C Fenselau; L P Johnson
Journal:  Drug Metab Dispos       Date:  1980 Jul-Aug       Impact factor: 3.922

4.  [Plasma level and effectiveness of propafenone and its organ distribution (author's transl)].

Authors:  H Blanke; B Aschbrenner; K R Karsch; H Kreuzer
Journal:  Dtsch Med Wochenschr       Date:  1979-04-20       Impact factor: 0.628

5.  Electron impact fragmentation studies of beta-blocking drugs and their metabolites by GC-mass spectroscopy.

Authors:  D A Garteiz; T Walle
Journal:  J Pharm Sci       Date:  1972-11       Impact factor: 3.534

6.  The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans.

Authors:  K J Hoffmann; A Arfwidsson; K O Borg
Journal:  Drug Metab Dispos       Date:  1982 Mar-Apr       Impact factor: 3.922

7.  New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation.

Authors:  T Walle; J E Oatis; U K Walle; D R Knapp
Journal:  Drug Metab Dispos       Date:  1982 Mar-Apr       Impact factor: 3.922

8.  A quantitative method for the chromatographic separation of 17-oxo steroid sulphates from 17-oxo steroid glucuronides with observations on the behaviour of conjugated corticosteroids on the same system.

Authors:  J J BARLOW; A E KELLIE
Journal:  Biochem J       Date:  1959-01       Impact factor: 3.857

  8 in total
  13 in total

1.  Tissue distribution of propafenone in the rat after intravenous administration.

Authors:  J Fernández; L Lligoña; A Puigdemont; R Guitart; J L Riu; M Arboix
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

2.  Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses.

Authors:  L Frabetti; B Marchesini; A Capucci; C Cavallini; S Gubelli; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.

Authors:  P Giani; M Landolina; V Giudici; C Bianchini; G Ferrario; S Marchi; E Riva; R Latini
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1987-12       Impact factor: 9.546

5.  Drug interaction between propafenone and metoprolol.

Authors:  F Wagner; D Kalusche; D Trenk; E Jähnchen; H Roskamm
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

6.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

Authors:  R Latini; M Belloni; R Bernasconi; E Cappiello; P Giani; M Landolina; D Leopaldi; J M Castel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 7.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

8.  Effects of 5-hydroxy-propafenone in guinea-pig atrial fibres.

Authors:  C Delgado; J Tamargo; T Tejerina; C Valenzuela
Journal:  Br J Pharmacol       Date:  1987-03       Impact factor: 8.739

9.  Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo.

Authors:  B Reder-Hilz; M Ullrich; M Ringel; N Hewitt; D Utesch; F Oesch; J G Hengstler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-03-04       Impact factor: 3.000

Review 10.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.